Educational Objectives • Review recent clinical updates of RET inhibitors and how they fit into the treatment paradigm for non‒small cell lung cancer • Identify and manage adverse effects of RET inhibitors to ensure patient safety and improve adherence Moderator:
Lauren Ledbetter, PharmD, BCOP Clinical Pharmacy Specialist, Thoracic Medical Oncology The James Cancer Hospital at The Ohio State University Columbus, Ohio Faculty: Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Clinical Pharmacy Manager University of Kansas
Cancer Center Division of Hematologic Malignancies & Cellular Therapeutics Disclosures Lauren Ledbetter, PharmD, BCOP, has the following financial relationships with commercial interests to disclose: Consultant: The Dedham Group, Charles River Associates Speakers
Bureau: APPOS Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, has the following financial relationships with commercial interests to disclose: Consultant: Pfizer, Sanofi, Genmab, Janssen Accreditation: Pharmacy Times Continuing Education™ is accredited by the
Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.5 CEU) under the ACPE universal activity number 0290-0000-24-304-H01-P. The activity is available for CE credit
through October 31, 2025. Supporter: This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.
PodQuest PodQuest Podcast Discovery Engine